Welcome to our dedicated page for Painreform news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on Painreform stock.
PainReform Ltd (PRFX) is a clinical-stage pharmaceutical innovator developing advanced pain management solutions through therapeutic reformulation. This page aggregates official announcements, clinical trial updates, and strategic developments related to the company’s extended-release drug-delivery platform.
Investors and healthcare professionals will find timely updates on PRF-110’s progress through FDA pathways, postoperative analgesia research, and operational milestones. The curated news collection serves as a centralized resource for tracking the company’s unique approach to reducing opioid reliance via localized, sustained pain relief therapies.
Key content categories include clinical trial results, regulatory filings, partnership announcements, and scientific presentations. All materials are sourced from verified channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to PainReform’s latest developments in drug reformulation technology and its evolving position within the specialty pharmaceuticals sector.
PainReform (Nasdaq: PRFX) commenced development of OcuRing-K, LayerBio’s intraoperatively administered, erodible sustained‑release ocular device, and is advancing toward a Phase II clinical trial for post‑cataract pain and inflammation.
OcuRing‑K delivers controlled ketorolac release to target tissues, aims to replace multi‑week eye‑drop regimens, and showed pain and inflammation reductions in preclinical studies and a Phase I evaluation with lower total drug exposure. The program targets the large cataract surgery market (~4.5M US surgeries; ~$9B global annual procedure volume) and may expand to additional ophthalmic indications pending further clinical progress and regulatory approval.
PainReform (Nasdaq: PRFX) said DeepSolar has advanced development of an AI-driven automated reporting engine for solar-asset analysis.
The engine is designed to consolidate SCADA, monitoring, weather and market data, reduce manual aggregation, and deliver customized, insight-rich performance reports within minutes. Users can set analysis depth, visualization style, and reporting frequency to support operations, management and investor reporting.
PainReform (Nasdaq: PRFX) said its DeepSolar unit was featured in a Watchlist Interview after joining the NVIDIA Connect program, spotlighting development of DeepSolar Predict, an AI forecasting module for photovoltaic (PV) assets.
The system combines advanced weather modeling and AI to raise forecast resolution, help solar-asset managers reduce imbalance penalties, optimize energy-sale timing, and support pilot project progress toward commercial deployment.
PainReform (Nasdaq: PRFX) reported significant developments for H1 2025, marking a strategic shift into both pharmaceuticals and renewable energy. The company completed a majority investment in LayerBio, acquiring OcuRing™-K, a dropless cataract therapy targeting a $9B global market. Their pharmaceutical pipeline includes ongoing R&D for PRF-110, which showed early positive efficacy in postoperative pain.
The company's DeepSolar division achieved notable milestones, including the completion of MyDeepSolar app, acceptance into NVIDIA Connect Program, and conversion of a 92MW pilot with Econergy into their first commercial agreement. Financially, PainReform reduced its net loss to $2.3M from $12.8M year-over-year, maintaining $3.5M in cash and $1.5M in positive working capital.
PainReform (Nasdaq: PRFX) announced that its solar energy business unit, DeepSolar, has been accepted into the prestigious NVIDIA Connect Program. This collaboration will advance DeepSolar Predict, the company's AI-driven solar forecasting solution for photovoltaic systems.
The technology is expected to improve weather forecast accuracy by up to 50% and reduce operational and maintenance costs by up to 30%. DeepSolar Predict aims to help solar asset owners optimize energy sale timing, reduce forecast penalties, and strengthen grid stability through more predictable supply.
The NVIDIA Connect Program provides DeepSolar with access to AI frameworks, development tools, and engineering support, positioning the company to become a key player in performance-driven solar asset management.
PainReform (Nasdaq: PRFX) has completed a strategic investment in LayerBio, acquiring a majority equity stake to enter the $9 billion global cataract surgery market. The company's focus is on LayerBio's OcuRing™-K technology, a breakthrough non-opiate, non-steroidal postoperative drug delivery system.
OcuRing™-K is a bioerodible intraocular ring designed to deliver Ketoralac during cataract procedures, offering a "dropless" alternative to traditional postoperative eye drop regimens. The technology targets the U.S. market of 4.5 million annual cataract surgeries, valued at over $3 billion.
LayerBio's CEO Dr. Ken Mandell, a Harvard-trained ophthalmologist and biotechnology entrepreneur, will continue leading the company's operations and product development efforts. The companies plan to advance OcuRing™-K through clinical development in the U.S., with potential expansion into other ophthalmic applications.
PainReform (Nasdaq: PRFX) has announced a strategic investment agreement with LayerBio Inc., acquiring a majority equity stake and board position for up to $3 million in milestone-based investments. The deal expands PainReform's non-opiate pain management pipeline into ophthalmology.
LayerBio's lead product, OcuRing™-K, is a sustained-release intraocular ring delivering anti-inflammatory and analgesic agents post-cataract surgery, targeting a market of 3 million annual U.S. procedures. The initial investment of $600,000 will support a planned Phase II clinical trial, with remaining funds disbursed based on development milestones.
The transaction, expected to close by July 2025, will maintain LayerBio's current management under CEO Dr. Ken Mandell, a Harvard-trained ophthalmologist and biotechnology entrepreneur with extensive experience in drug delivery innovations.
Blade Ranger Ltd. (TASE: BLRN) announced a significant milestone in its transaction with PainReform (NASDAQ: PRFX) regarding the sale of its DeepSolar operations. Following increased software sales, Blade Ranger has received 685,004 warrants exercisable at $0.01 per share, with PainReform's shares trading at approximately $1.91. The March 2025 agreement initially provided Blade Ranger with approximately 9.9% equity in PainReform and 3.08 million warrants. Currently, Blade Ranger holds shares and warrants worth approximately $2 million based on the current share price, with the matured warrants valued at approximately NIS 4.5 million.
PainReform (NASDAQ: PRFX) has launched a strategic pilot program with Econergy Renewable Energy to implement its DeepSolar™ AI platform at one of Romania's largest solar facilities. The pilot will take place at Econergy's 92-megawatt photovoltaic plant in Parau, Romania.
The DeepSolar™ platform will analyze real-time and historical data to optimize operational efficiency and energy yield. Upon successful completion, the program may expand across Econergy's portfolio, potentially reaching 1 Gigawatt of total capacity. The partnership aims to demonstrate how AI-powered solutions can enhance performance and reduce costs in utility-scale solar operations.
Econergy, headquartered in Israel, operates across Europe with approximately 1 gigawatt of photovoltaic capacity either operational or under construction.
PainReform (Nasdaq: PRFX) announced its expansion into the Smart Energy Management sector through the acquisition of DeepSolar, an AI-driven solar optimization software provider. The strategic move marks a significant shift from the company's pharmaceutical focus to tech-enabled markets.
DeepSolar's flagship product, MyDeepSolar, is an application that uses machine learning and predictive analytics to optimize solar energy systems for residential users. The platform offers real-time monitoring, yield forecasting, and performance optimization features to help homeowners maximize their solar investments.
According to Ehud Geller, Chairman and interim CEO, this expansion aligns with global energy trends and leverages a commercially scalable technology platform. The move comes amid increased M&A activity in the solar sector and growing government support through tax credits and smart grid infrastructure initiatives.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
